Tatung : Announcement of the resolution of purchase the minority equity of Tatung Medical & Healthcare Technologies Co., Ltd..

Close

Today's Information

Provided by: TATUNG CO.
SEQ_NO	1	Date of announcement	2022/03/03	Time of announcement	19:05:35
Subject	Announcement of the resolution of purchase the minority equity of Tatung Medical & Healthcare Technologies Co., Ltd..
Date of events	2022/03/03	To which item it meets	paragraph 20
Statement	1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.):Common shares of Tatung Medical & Healthcare Technologies Co., Ltd. 2.Date of occurrence of the event:2022/03/03 3.Amount, unit price, and total monetary amount of the transaction: Volume：1,577,067 shares Unit price：NT$5.60 per share Total monetary amount：NT$ 8,831,575 4.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): Individual shareholder; No. 5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer:N/A 6.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction:N/A 7.Matters related to the current disposal of creditors' rights (including types of collaterals of the disposed creditor's rights; if creditor's rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor's rights, currently being disposed of, over such related party):N/A 8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (those with deferral should provide a table explaining recognition):N/A 9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions: Paying in cash. 10.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making unit: Refer to Adopted by Tatung investment review committee. (Approved by the President according to the level of authority.) 11.Net worth per share of the Company's underlying securities acquired or disposed of: NT$ 5.95 per share. 12.Cumulative no.of shares held (including the current transaction), their monetary amount, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment: Current cumulative volume: 38,001,306 shares； Current cumulative amount: NT$ 440,104 thousand； Shareholding percentage: 100%； No restriction of rights. 13.Current ratio of securities investment (including the current trade, as listed in article 3 of Regulations Governing the Acquisition and Disposal of Assets by Public Companies) to the total assets and equity attributable to owners of the parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present: Current ratio to the total assets: 63.53 %, Current ratio shareholder's equity: 146.37%, The operating capital: NTD -2,689,551 thousand. 14.Broker and broker's fee:N/A 15.Concrete purpose or use of the acquisition or disposal: In order to make the group's operational strategy implementation and administrative procedures more flexible, we plans to purchase a minority equity in Tatung Medical & Healthcare Technologies Co., Ltd., making Tatung Medical & Healthcare Technologies Co., Ltd. becomes a wholly-owned subsidiary of the company. 16.Any dissenting opinions of directors to the present transaction:N/A 17.Whether the counterparty of the current transaction is a related party:None 18.Date of the board of directors resolution:NA 19.Date of ratification by supervisors or approval by the Audit Committee:NA 20.Whether the CPA issued an unreasonable opinion regarding the current transaction:N/A 21.Name of the CPA firm:N/A 22.Name of the CPA:N/A 23.Practice certificate number of the CPA:N/A 24.Whether the transaction involved in change of business model:None 25.Details on change of business model:N/A 26.Details on transactions with the counterparty for the past year and the expected coming year:None 27.Source of funds:The Company's operating funds. 28.Any other matters that need to be specified: According to authorization of company and the regulation of acquisition or disposal, and the letter from the TWSE announcement.